ProCE Banner Activity

Frequently Asked Questions on Recent Approvals and Novel Therapies in Cervical Cancer

Clinical Thought

Read this commentary from cervical cancer experts discussing recent approvals and adverse events management recommendations for novel therapies in patients with cervical cancer.

Released: June 09, 2022

Expiration: June 08, 2023

No longer available for credit.

Share

Faculty

Maria Avila-Wallace

Maria Avila-Wallace, NP

Nurse Practitioner
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Massachusetts General Hospital
Boston, Massachusetts

Lauren Prescott

Lauren Prescott, MD, MPH

Assistant Professor, Obstetrics and Gynecology
Division of Gynecologic Oncology
Vanderbilt University Medical Center
Nashville, Tennessee

Acknowledgement

This activity is supported by an educational grant from Genmab and Seagen.

Supporters

Genmab

Seagen

Target Audience

Oncology NPs, PAs, and nurses

Disclosure

Maria Avila-Wallace, NP, has no relevant financial relationships to disclose.

Lauren Prescott, MD: consultant: Tempus.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.

Format

ClinicalThought

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Additional Information

Program Medium

This program has been made available online.